ESSA Bancorp(ESSA) Prnewswire·2025-02-25 10:45Core Viewpoint - A class action securities lawsuit has been filed against ESSA Pharma Inc. due to alleged securities fraud affecting investors between December 12, 2023, and October 31, 2024 [1][2]. Group 1: Allegations and Claims - The lawsuit claims that the defendants made false statements regarding the efficacy of masofaniten in combination with enzalutamide, suggesting it had no clear benefit over enzalutamide alone [2]. - It is alleged that masofaniten was less effective in treating prostate cancer than previously communicated to investors [2]. - The M-E Combination Study, which was intended to evaluate the treatment's effectiveness, is said to be unlikely to meet its Phase 2 primary endpoint as previously stated [2]. - The defendants are accused of overstating masofaniten's clinical, regulatory, and commercial prospects, leading to materially false and misleading public statements [2]. Group 2: Legal Process and Participation - Investors who suffered losses during the specified timeframe have until March 25, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require this role [3]. - Class members may be entitled to compensation without incurring any out-of-pocket costs or fees, and there is no obligation to participate [3]. Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and has been recognized as one of the top securities litigation firms in the United States for seven consecutive years [4].